Summary
S-Biomedic has developed a disruptive technology to directly modulate the skin microbiome, enabling a wide range of applications in dermatology. The first product is a cosmetic for acne prone skin (TRL6) with proven efficacy and safety in an area where competing products are either ineffective or cause severe side-effects.
Acne is amongst the 10 most prevalent diseases globally and the main reason for people to consult a dermatologist. It affects the life quality of millions of Europeans and represents a market of €4.4 billion. S-Biomedic’s novel skin probiotic product will be launched in 2021 in selected European countries, and will allow reducing current treatments from years to weeks and preventing the actual relapse episodes of acne.
S-Biomedic is leading the skin microbiome field based on a unique combination of approach, technology and careful IPR protection. Backed by global industrial partners with an unparalleled reputation in the personal care industries, such as Johnson & Johnson, DSM and Beiersdorf, S-Biomedic has successfully accelerated its R&D and turned its platform technology into a high-potential product pipeline. However, the ambitious challenge posed by the launch of a new cosmetic product in the market can only be met to its full potential with the support of the EIC pilot.
The SkinMicrobiome project will support S-Biomedic in the route to market and accelerate its growth, enabling sales >€55M by 2028, positioning it among the Top 10 acne brands globally, with a projected market share of 2,58%. SkinMicrobiome will allow to hire employees with commercial and marketing background, who will complement a multidisciplinary team led by excellent business and scientific professionals. SkinMicrobiome will become a key cornerstone for the successful launch of the first highly innovative cosmetic and will enable S-Biomedic to lead at the forefront of microbiome-based solutions not only in Europe but also on a global level.
Acne is amongst the 10 most prevalent diseases globally and the main reason for people to consult a dermatologist. It affects the life quality of millions of Europeans and represents a market of €4.4 billion. S-Biomedic’s novel skin probiotic product will be launched in 2021 in selected European countries, and will allow reducing current treatments from years to weeks and preventing the actual relapse episodes of acne.
S-Biomedic is leading the skin microbiome field based on a unique combination of approach, technology and careful IPR protection. Backed by global industrial partners with an unparalleled reputation in the personal care industries, such as Johnson & Johnson, DSM and Beiersdorf, S-Biomedic has successfully accelerated its R&D and turned its platform technology into a high-potential product pipeline. However, the ambitious challenge posed by the launch of a new cosmetic product in the market can only be met to its full potential with the support of the EIC pilot.
The SkinMicrobiome project will support S-Biomedic in the route to market and accelerate its growth, enabling sales >€55M by 2028, positioning it among the Top 10 acne brands globally, with a projected market share of 2,58%. SkinMicrobiome will allow to hire employees with commercial and marketing background, who will complement a multidisciplinary team led by excellent business and scientific professionals. SkinMicrobiome will become a key cornerstone for the successful launch of the first highly innovative cosmetic and will enable S-Biomedic to lead at the forefront of microbiome-based solutions not only in Europe but also on a global level.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: | https://cordis.europa.eu/project/id/890930 |
Start date: | 01-02-2020 |
End date: | 31-01-2022 |
Total budget - Public funding: | 1 856 055,00 Euro - 1 299 238,00 Euro |
Cordis data
Original description
S-Biomedic has developed a disruptive technology to directly modulate the skin microbiome, enabling a wide range of applications in dermatology. The first product is a cosmetic for acne prone skin (TRL6) with proven efficacy and safety in an area where competing products are either ineffective or cause severe side-effects.Acne is amongst the 10 most prevalent diseases globally and the main reason for people to consult a dermatologist. It affects the life quality of millions of Europeans and represents a market of €4.4 billion. S-Biomedic’s novel skin probiotic product will be launched in 2021 in selected European countries, and will allow reducing current treatments from years to weeks and preventing the actual relapse episodes of acne.
S-Biomedic is leading the skin microbiome field based on a unique combination of approach, technology and careful IPR protection. Backed by global industrial partners with an unparalleled reputation in the personal care industries, such as Johnson & Johnson, DSM and Beiersdorf, S-Biomedic has successfully accelerated its R&D and turned its platform technology into a high-potential product pipeline. However, the ambitious challenge posed by the launch of a new cosmetic product in the market can only be met to its full potential with the support of the EIC pilot.
The SkinMicrobiome project will support S-Biomedic in the route to market and accelerate its growth, enabling sales >€55M by 2028, positioning it among the Top 10 acne brands globally, with a projected market share of 2,58%. SkinMicrobiome will allow to hire employees with commercial and marketing background, who will complement a multidisciplinary team led by excellent business and scientific professionals. SkinMicrobiome will become a key cornerstone for the successful launch of the first highly innovative cosmetic and will enable S-Biomedic to lead at the forefront of microbiome-based solutions not only in Europe but also on a global level.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all